Skip to main content
Signal8
Launch Terminal

Whitehawk Therapeutics, Inc. (WHWK)

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Whitehawk Therapeutics Inc logo

Whitehawk Therapeutics Inc

NASDAQ:WHWKHealthcare
-1.82%$3.24
AH$3.24+0.00%vs close
Mkt Cap$184.71M
Float39.34M
O/S57.01M
Vol
$ Vol
RVOL
Inst Own75.8%
SI6.7%
Earnings
Dilution
Whitehawk Therapeutics Inc logoNASDAQ:WHWK$3.24-1.82%
Phase Distribution
19 lead-sponsored trials·3 active·14 completed
Phase 17
Phase 1/23
Phase 28
Not applicable1
(8 more as collaborator)
Status Overview
Recruiting3
Completed14
Stopped1
Expanded access1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Completed

    The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema

    AKB-9778, ranibizumab

    Diabetic Macular Edema (DME)

    Enrollment
    144
    Start
    Jan 2014
    Primary Completion
    Apr 2015
    Completion
    May 2015
    NCT02050828
  • Phase 2
    Completed

    Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO

    AKB-9778

    Retinal Vein Occlusion

    Enrollment
    16
    Start
    Jan 2015
    Primary Completion
    Apr 2017
    Completion
    Apr 2017
    NCT02387788
  • Phase 2
    Completed

    A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa

    nab-Sirolimus

    Malignant PEComa

    Enrollment
    34
    Start
    Oct 2015
    Primary Completion
    Nov 2021
    Completion
    Apr 2022
    NCT02494570
  • Phase 2
    Completed

    Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

    nab-sirolimus, nab-sirolimus + temozolomide

    High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma

    Enrollment
    62
    Start
    Aug 2018
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT03463265
  • Phase 2
    Withdrawn

    ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome

    ABI-009

    Leigh Syndrome

    Enrollment
    0
    Start
    Apr 2022est.
    Primary Completion
    Dec 2024est.
    Completion
    Mar 2025est.
    NCT03747328
  • Phase 2
    Completed

    Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

    nab-sirolimus

    Tumor, Tumor, Solid +19

    Enrollment
    128
    Start
    Mar 2022
    Primary Completion
    Dec 2024
    Completion
    Dec 2024
    NCT05103358
  • Phase 2
    Recruiting

    Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

    nab-sirolimus

    Endometrial Cancer, Endometrioid Tumor +4

    Enrollment
    29
    Start
    Dec 2023
    Primary Completion
    Dec 2026est.
    Completion
    Jun 2027est.
    NCT05997017
  • Phase 2
    Completed

    Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

    nab-sirolimus

    Neuroendocrine Tumors, NET +3

    Enrollment
    12
    Start
    Oct 2023
    Primary Completion
    Oct 2025
    Completion
    Oct 2025
    NCT05997056
  • Phase 1/2
    Completed

    Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema

    Subcutaneous AKB-9778

    Diabetic Macular Edema (DME)

    Enrollment
    24
    Start
    Sep 2012
    Primary Completion
    Sep 2013
    Completion
    Dec 2014
    NCT01702441
  • Phase 1/2
    Completed

    Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

    ABI-009, Gemcitabine

    Non-muscle Invasive Bladder Cancer (NMIBC)

    Enrollment
    21
    Start
    Apr 2014
    Primary Completion
    Dec 2019
    Completion
    Dec 2019
    NCT02009332
  • Phase 1/2
    Completed

    Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

    nab-sirolimus

    Colorectal Cancer Metastatic

    Enrollment
    60
    Start
    Jul 2018
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT03439462
  • Phase 1
    Completed

    Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension

    nab-sirolimus

    Pulmonary Hypertension

    Enrollment
    15
    Start
    Apr 2017
    Primary Completion
    Aug 2022
    Completion
    Sep 2022
    NCT02587325
  • Phase 1
    Completed

    Study to Assess the Absorption, Metabolism, Excretion and Pharmacokinetics of [14C]-AKB-9778

    AKB-9778 subcutaneous injection

    Healthy

    Enrollment
    6
    Start
    Jul 2016
    Primary Completion
    Jul 2016
    Completion
    Jul 2016
    NCT02858271
  • Phase 1
    Completed

    Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers

    AKB-4924

    IBD

    Enrollment
    40
    Start
    Aug 2016
    Primary Completion
    Nov 2016
    Completion
    Jan 2017
    NCT02914262
  • Phase 1
    Completed

    Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

    AKB-9778 Ophthalmic Solution, Placebo Ophthalmic Solution

    Ocular Hypertension, Primary Open Angle Glaucoma

    Enrollment
    91
    Start
    May 2019
    Primary Completion
    Dec 2019
    Completion
    Dec 2019
    NCT04284514
  • Phase 1
    Completed

    Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

    nab-sirolimus

    Tumor, Solid, Tumor +1

    Enrollment
    15
    Start
    Nov 2022
    Primary Completion
    Aug 2025
    Completion
    Sep 2026
    NCT05661461
  • Phase 1
    Recruiting

    Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

    HWK-007

    Endometrial Cancer, Ovarian Cancer +5

    Enrollment
    226
    Start
    Dec 2025
    Primary Completion
    Oct 2028est.
    Completion
    Dec 2028est.
    NCT07444814
  • Phase 1
    Recruiting

    A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

    HWK-016, MUCIN-16-targeted ADC, Bevacizumab

    PROC, Platinum Resistant Ovarian Cancer +1

    Enrollment
    265
    Start
    Mar 2026
    Primary Completion
    Feb 2028est.
    Completion
    Feb 2028est.
    NCT07470853
  • Expanded access
    Approved for marketing

    Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

    ABI-009

    PEComa, Malignant, TSC1 +2

    Enrollment
    -
    Start
    -
    Primary Completion
    -
    Completion
    -
    NCT03817515
Search ClinicalTrials.gov for “Whitehawk Therapeutics”